Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego.

ABSTRACT:

Background

The diversity in the genomic landscape of advanced and metastatic tumors calls for combination therapies based on the genomic signature associated with each tumor. Determining safe and tolerable doses for novel combinations of oncology drugs is essential for a precision medicine approach, but can also require dose reductions. Trametinib, palbociclib, and everolimus are among the targeted therapies most often used in novel combinations at our precision medicine clinic.

Objective

To evaluate the safe, tolerable dosing of trametinib, palbociclib, and everolimus when used as part of novel combinations with other agents for the treatment of advanced or metastatic solid tumors.

Methods

This retrospective study included adult patients with advanced or metastatic s

SUBMITTER: Nikanjam M 

PROVIDER: S-EPMC10054256 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature